Ondansetron Hydrochloride vials recalled due to sterility assurance concerns
Olympia Compounding Pharmacy recalls 911 vials of Ondansetron Hydrochloride (1 mg/mL) due to lack of sterility assurance. The product was distributed nationwide in the USA, Puerto Rico, and US Virgin Islands.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a parenteral drug product with sterility assurance concerns. While no illnesses or injuries have been reported, the theoretical risk of infection from an injectable product with unassured sterility qualifies as a risk-of-harm product where injury has not yet been reported, meeting the High severity criterion.
Plain-English summary
Olympia Compounding Pharmacy is recalling 911 vials of Ondansetron Hydrochloride, 1 mg/mL, Multi-Dose 30 mL vials (NDC 73198-0127-30). The recalled lot is B24015-22 with a Beyond Use Date of 8/15/2022.
The product is being recalled because the manufacturer cannot assure that the vials maintain their sterility. This is a significant concern for multi-dose vials intended for injection, as lack of sterility can pose a risk of infection.
The recalled vials were distributed nationwide in the United States, Puerto Rico, and the U.S. Virgin Islands.
Patients and healthcare providers who have received this product should discontinue use immediately and consult with their healthcare provider about alternative treatments. Healthcare facilities should verify their inventory against the lot number and remove any affected product from circulation.
The recalled product
- Product
- Ondansetron Hydrochloride, 1 mg/mL, Multi-Dose 30 mL vial, Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155 Orlando, FL 32835. NDC 73198-0127-30.
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Injectable
- Hazard
- sterility-failure
- contamination-risk
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: B24015-22 BUD: 8/15/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27